Dexlansoprazole delayed release (dexlansoprazole) NDC 50090-5944

NDC codes

FDA NDC Directory

Product NDC (as listed)50090-5944Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50090-5944Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
50090-5944-0	50090594400	30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (50090-5944-0)Marketed from Mar 17, 2022
50090-5944-1	50090594401	90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (50090-5944-1)Marketed from Apr 1, 2022

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Dexlansoprazole delayed releaseSuffix: delayed release
Generic name (nonproprietary): dexlansoprazole
Active ingredients: Dexlansoprazole — 60 mg/1
Dosage form: Capsule, Delayed release
Route: Oral
Labeler: A-S Medication Solutions
Product type: Prescription drug
Marketing category: NDA authorized genericApplication NDA 022287
Marketing start: Jan 1, 2022
Listing expires: Dec 31, 2026
Other FDA classes: Proton Pump Inhibitors (Mechanism)
Identifiers: Product ID 50090-5944_275745bb-b010-45d6-9541-78d365e2dd46SPL ID 275745bb-b010-45d6-9541-78d365e2dd46SPL set ID 7c7698da-3cda-4301-ae93-02fb64b9c90dRxCUI 833213UNII UYE4T5I70X
Pharmacologic class: Proton Pump Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N450090594400 followed by a unit qualifier and the quantity

Package 50090-5944-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 22, 2023.

Indications (excerpt from the label)

Dexlansoprazole delayed-release capsules are proton pump inhibitor (PPI) indicated in patients 12 years of age and older for: Healing of all grades of erosive esophagitis (EE). ( 1.1 ) Maintenance of healed EE and relief of heartburn. ( 1.2 ) Treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD). ( 1.3 ) 1.1 Healing of Erosive Esophagitis Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for healing of all grades of erosive esophagitis (EE) for up to eight weeks. 1.2 Maintenance of Healed Erosive Esophagitis and Relief of Heartburn Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older to m…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 022287

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 022287
Product	Strength	Form · route	Labeler	Product NDC
Dexilantdexlansoprazole	Dexlansoprazole 30 mg/1	Capsule, Delayed releaseOral	Takeda Pharmaceuticals America, Inc.	64764-171
Dexilantdexlansoprazole	Dexlansoprazole 60 mg/1	Capsule, Delayed releaseOral	Takeda Pharmaceuticals America, Inc.	64764-175